French pharmaceutical company said drug could treat COVID-19 patients after promising test results

19 March 2020
557 Views

A leading French pharmaceutical company said it could potentially treat 300,000 COVID-19 patients with the anti-malarial drug Plaquenil after what it described as “promising” test results.

Sanofi said it was ready to offer France millions of doses of Plaquenil, a spokesperson for the laboratory told AFP, adding that the group was ready to work with French health authorities “to confirm these results.”

The study on 24 patients with coronavirus using Plaquenil, a hydroxychloroquine molecule, which has also been used for decades for the treatment of autoimmune diseases like lupus or rheumatoid arthritis.

Six days after the start of taking Plaquenil, the virus had disappeared in three-quarters of those treated, said Professor Didier Raoult, who is director of the Institut Hospitalo-Universitaire de Marseille.

The French government said the clinical trials were “promising” and would be extended to more patients.

source: arabnews.com

You may be interested

Coronavirus Greece: 1,269 new cases, 379 intubated, 36 deaths
GREECE
shares20 views
GREECE
shares20 views

Coronavirus Greece: 1,269 new cases, 379 intubated, 36 deaths

Panos - Mar 01, 2021

The Greek authorities announced today the new laboratory-confirmed cases of the coronavirus that were recorded in the last 24 hours…

BBC: The last speakers of Ancient Sparta
GREECE
shares44 views
GREECE
shares44 views

BBC: The last speakers of Ancient Sparta

Panos - Feb 26, 2021

As you enter the mountainous village of Pera Melana in Greece’s southern Peloponnese peninsula, you’re likely to hear the roar of…

Coronavirus Greece: 1,784 new cases, 367 intubated, 39 deaths
GREECE
shares61 views
GREECE
shares61 views

Coronavirus Greece: 1,784 new cases, 367 intubated, 39 deaths

Panos - Feb 26, 2021

Greece announced today that the new laboratory confirmed cases of the disease recorded in the last 24 hours are 1,784, of…

Leave a Comment

Your email address will not be published.